Trials that use: Covariate adjustment
3,935 results
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007): Complete Statistical AnalysisIndependent statistical analysis of A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007): primary endpoint results, effect estimate with confidence…
- A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B: Complete Statistical AnalysisIndependent statistical analysis of A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B: primary endpoint results, effect estimate with confidence…
- A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2): Complete Statistical AnalysisIndependent statistical analysis of A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2): primary…
- A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia: Complete Statistical AnalysisIndependent statistical analysis of A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis: primary endpoint results, effect estimate with confidence…
- A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I): Complete Statistical AnalysisIndependent statistical analysis of A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn: Complete Statistical AnalysisIndependent statistical analysis of A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy: Complete Statistical AnalysisIndependent statistical analysis of A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy: primary endpoint results, effect estimate with confidence interval,…
- A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty: Complete Statistical AnalysisIndependent statistical analysis of A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase: Complete Statistical AnalysisIndependent statistical analysis of A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Study of E7820 in People With Bone Marrow (Myeloid) Cancers: Complete Statistical AnalysisIndependent statistical analysis of A Study of E7820 in People With Bone Marrow (Myeloid) Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer: primary…
- A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203): Complete Statistical AnalysisIndependent statistical analysis of A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158): Complete Statistical AnalysisIndependent statistical analysis of A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of Fisetin to Treat Carpal Tunnel Syndrome: Complete Statistical AnalysisIndependent statistical analysis of A Study of Fisetin to Treat Carpal Tunnel Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05416515).
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors: Complete Statistical AnalysisIndependent statistical analysis of A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of FMT in Patients With AML Allo HSCT in Recipients: Complete Statistical AnalysisIndependent statistical analysis of A Study of FMT in Patients With AML Allo HSCT in Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04085289).
- A Study of Galcanezumab in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of Galcanezumab in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02576951).
- A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive…
- A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM): Complete Statistical AnalysisIndependent statistical analysis of A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: primary endpoint results, effect…
- A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy: Complete Statistical AnalysisIndependent statistical analysis of A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Immunogenicity and Safety of GSK Biologicals’ Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older: Complete Statistical AnalysisIndependent statistical analysis of A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy: primary endpoint results, effect estimate with confidence…
- A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.: Complete Statistical AnalysisIndependent statistical analysis of A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease: primary endpoint results, effect estimate with confidence…
- A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection: Complete Statistical AnalysisIndependent statistical analysis of A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza: Complete Statistical AnalysisIndependent statistical analysis of A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03073213).
- A Study of Ixekizumab in Participants With Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ixekizumab in Participants With Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02993471).
- A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers: Complete Statistical AnalysisIndependent statistical analysis of A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy: Complete Statistical AnalysisIndependent statistical analysis of A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH): Complete Statistical AnalysisIndependent statistical analysis of A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH): primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Study of Lasmiditan in Healthy Chinese Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of Lasmiditan in Healthy Chinese Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04081324).
- A Study of Lasmiditan in Healthy Elderly Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of Lasmiditan in Healthy Elderly Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03406260).
- A Study of Lasmiditan in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of Lasmiditan in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03182920).
- A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus: Complete Statistical AnalysisIndependent statistical analysis of A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus: primary endpoint results, effect estimate…
- A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of LY2189102 in Patients With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY2189102 in Patients With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00942188).
- A Study of LY2624803 in Japanese Participants With Transient Insomnia: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY2624803 in Japanese Participants With Transient Insomnia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01784614).
- A Study of LY3006072 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3006072 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01640249).
- A Study of LY3041658 in Adults With Hidradenitis Suppurativa: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3041658 in Adults With Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04493502).